Uğur Şahin

Uğur Şahin
BioNTech · CC BY-SA 4.0 · source
Name	Uğur Şahin
Birth date	1965
Birth place	İskenderun, Turkey
Nationality	German
Occupation	Physician, Immunologist, Entrepreneur
Known for	Co-founder and CEO of BioNTech; mRNA vaccine development

Uğur Şahin is a German physician, immunologist, and entrepreneur known for co-founding BioNTech and leading development of an mRNA-based vaccine during the COVID-19 pandemic. He trained in medicine and oncology, pursued translational cancer immunotherapy research, and forged partnerships with academic, industrial, and governmental institutions to accelerate vaccine and immunotherapy platforms. Şahin has received multiple scientific awards and has engaged in public discourse on pandemic preparedness and biotechnology policy.

Early life and education

Şahin was born in İskenderun and moved to Germany, where he studied medicine at the University of Cologne and worked at the University Hospital Cologne. He completed doctoral research with links to University of Mainz and clinical training that connected him to University of Hamburg and University Medical Center Mainz. His early mentors and collaborators included researchers from German Cancer Research Center and Max Planck Institute for Biochemistry. During training he engaged with programs at Ludwig Maximilian University of Munich and institutions like Charité – Universitätsmedizin Berlin and Heidelberg University Hospital through research exchanges and conferences hosted by European Society for Medical Oncology and American Association for Cancer Research.

Scientific career and research

Şahin’s scientific career spans oncology, immunology, and personalized medicine with research collaborations involving National Institutes of Health, European Molecular Biology Laboratory, and Wellcome Trust-affiliated groups. His work focused on tumor immunology, dendritic cell biology, neoantigen prediction and individualized cancer vaccines, intersecting with technologies from CRISPR-Cas9 research teams, next-generation sequencing centers at Broad Institute, and computational immunology groups at European Bioinformatics Institute. He published and presented findings at meetings such as American Society of Clinical Oncology, European Association for Cancer Research, and International Congress of Immunology, and collaborated with investigators at Massachusetts Institute of Technology, Harvard Medical School, and University of Oxford. His translational efforts involved partnerships with biotechnology firms including Roche, Novartis, Pfizer, GlaxoSmithKline, and startups emerging from Cambridge Biomedical Campus and Biotech Triangle hubs.

Founding and leadership of BioNTech

Şahin co-founded BioNTech with colleagues and assumed the role of CEO, guiding organizational strategy, scientific direction, and corporate partnerships. Under his leadership BioNTech established research sites in collaboration with European Investment Bank initiatives, negotiated manufacturing with firms like Catalent and Lonza, and entered strategic alliances with Pfizer and investors including Goldman Sachs and Fidelity Investments. The company expanded into programs spanning oncology, infectious diseases, and rare diseases, collaborating with academic centers such as Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, and Johns Hopkins University. BioNTech’s corporate governance engaged advisors from World Health Organization, Bill & Melinda Gates Foundation, and regulatory dialogue with European Medicines Agency and U.S. Food and Drug Administration.

mRNA vaccine development and COVID-19 response

Şahin directed rapid adaptation of mRNA platforms to SARS‑CoV‑2, coordinating teams that integrated preclinical work from groups at Institut Pasteur, Karolinska Institutet, and Tokyo University. BioNTech’s mRNA candidate underwent clinical trials conducted with partners at University of Freiburg, Icahn School of Medicine at Mount Sinai, and trial networks supported by Coalition for Epidemic Preparedness Innovations and Operation Warp Speed-era collaborations. Emergency use discussions involved Paul-Ehrlich-Institut, Centers for Disease Control and Prevention, and national health ministries across Germany, United States, United Kingdom, and European Union member states. Şahin participated in public briefings alongside officials from Bundeskanzleramt, U.S. Department of Health and Human Services, and multilateral forums such as G7 and G20, while BioNTech scaled manufacturing through partnerships with Samsung Biologics, Sanofi, and contract manufacturers in networks linked to ASEAN and African Union procurement initiatives.

Awards, honors, and recognitions

Şahin has received scientific and civic recognition from institutions including German Cancer Society, Royal Society of Medicine, Humboldt Foundation, and national orders from Germany and European science academies. He was acknowledged in listings by Time (magazine), Forbes, and Nature, and received honorary presidencies and lectureships from Max Delbrück Center for Molecular Medicine, Leopoldina, and Karlsruhe Institute of Technology. His leadership led to awards from philanthropic organizations such as Wellcome Trust affiliates and industry accolades from European Federation of Pharmaceutical Industries and Associations and international honors presented at venues including Palais des Nations and scientific meetings at Cold Spring Harbor Laboratory.

Personal life and public engagement

Şahin maintains ties with academic networks at University of Cologne, Mainz University Medical Center, and research consortia involving European Molecular Biology Organization. He engages publicly on topics with stakeholders like World Economic Forum panels, European Commission advisory boards, and media outlets including BBC, The New York Times, and Der Spiegel. Şahin contributes to policy discussions with think tanks such as Chatham House and participates in philanthropic initiatives alongside entities like Wellcome Trust and Bill & Melinda Gates Foundation. He has supported educational collaborations with institutions such as Technical University of Munich and outreach programs linked to Max Planck Society.

Category:German physicians Category:Immunologists Category:Biotech entrepreneurs